There was no evidence of inferiority in cost outcomes in the CRP-guided group, with total COPD-related cost at 6 months (including baseline) for the EQ-5D MITT population of £309.93 (SD=£941.03) per person in the CRP-guided group (n=301) and £300.97 (SD=£697.08) in the usual-care group (n=301). This evidence concerns the gene CRP and chronic obstructive pulmonary disease.